Jordan Armstrong outlines how adaptable DTP programs can reduce barriers and accelerate patient access to therapy. As direct-to-patient (DTP) models continue to gain traction across the pharmaceutical ...
The United States healthcare system is failing. We rank last among developed countries in healthcare performance, and Americans face lower life expectancy and growing chronic disease rates despite ...
Laura Blair discusses how DTP models make manufacturers rethink traditional access and distribution strategies.
That question, which few foresaw 12 months ago, reflects the fast rise of direct-to-patient (DTP) programs. In the last few months alone, Amgen, Bristol Myers Squibb, AstraZeneca, Genentech, Novartis ...
A recent survey shows that healthcare professionals have varied feelings on the direct-to-patient (DTP) drug sale platforms increasingly being launched by pharma companies—echoing patients’ own ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results